Clinical Trials Logo

Digestive System Neoplasms clinical trials

View clinical trials related to Digestive System Neoplasms.

Filter by:

NCT ID: NCT00826410 Completed - Clinical trials for Digestive System Neoplasms [C04.588.274]

Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The aim of the study is to determine wether subcutaneus suction drain (type redon-drain) protect against surgical side infection by laparotomy in general surgery.

NCT ID: NCT00793871 Completed - Clinical trials for Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

GIST
Start date: November 2008
Phase: Phase 4
Study type: Interventional

To investigate safety and efficacy of single agent sunitinib malate in Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.

NCT ID: NCT00767234 Terminated - Pancreatic Cancer Clinical Trials

Permission to Collect Blood Over Time for Research

Start date: August 2008
Phase: N/A
Study type: Observational

To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.

NCT ID: NCT00725712 Completed - Clinical trials for Neoplasms, Gastrointestinal Tract

Study of GSK1363089 in Metastatic Gastric Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

NCT ID: NCT00680901 Active, not recruiting - Clinical trials for Neoplasms, Gastrointestinal Tract

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Start date: June 4, 2008
Phase: Phase 3
Study type: Interventional

This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo.

NCT ID: NCT00640692 Withdrawn - Clinical trials for Gastrointestinal Neoplasm

Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial

Start date: December 2007
Phase:
Study type: Observational

The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial. Tumor samples will be screened for mutations and this information will be used to determine whether the progression-free survival of patients being treated with the cancer medication sunitinib is related to the underlying genotype of their GIST.

NCT ID: NCT00584363 Completed - Pancreatic Cancer Clinical Trials

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection

SPORE
Start date: June 2004
Phase: N/A
Study type: Observational

The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.

NCT ID: NCT00570635 Completed - Clinical trials for Gastrointestinal Stromal Tumors

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.

NCT ID: NCT00526669 Completed - Clinical trials for Neoplasms, Gastrointestinal Tract

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.

NCT ID: NCT00486954 Completed - Clinical trials for Neoplasms, Gastrointestinal Tract

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Start date: July 2007
Phase: Phase 3
Study type: Interventional

EGF104578 is two-part study (Pilot part/Randomized part).Pilot part is designed to find the optimal (best) doses of lapatinib and paclitaxel when given together,Randomized part is designed to evaluate the overall survival in patients receiving lapatinib and paclitaxel compared to patients receiving only paclitaxel.